10.1016/j.ejmech.2021.113256
The study presents the design and synthesis of a novel class of diaryl-substituted 2H-azirines, which are hybrid antitumor agents targeting both tubulin and DNA. These compounds were developed by combining pharmacophores from Combretastatin A-4 (CA-4), a known tubulin polymerization inhibitor, and aziridine-type alkylating agents, which are DNA damaging agents. The primary aim was to evaluate the antitumor activities of these compounds in vitro against various cancer cell lines and to investigate their mechanism of action. The most potent compound, 6h, showed significant activity against four cancer cell lines with low IC50 values and demonstrated dual-targeting capabilities in mechanistic studies. It inhibited tubulin polymerization, induced DNA damage, triggered cellular apoptosis, and showed anti-angiogenic effects. The study also included in vivo testing in a nude mice xenograft model, where 6h significantly inhibited tumor growth with low toxicity, indicating its potential for further development as a novel cancer therapy with a unique mechanism of action.